Achilles Therapeutics

64 articles about Achilles Therapeutics

• Achilles Therapeutics to Present at Upcoming Investor Conferences in September 2021

  9/2/2021

  Achilles Therapeutics plc, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, announced that management will present at the following investor conferences in September.

• Achilles Therapeutics Announces Grant of US and European Patents

  8/25/2021

  Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that US patent US 11,098,121 and European patent EP3347039B have been granted.

• Achilles Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights

  8/10/2021

  Achilles Therapeutics plc, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, announced its financial results for the second quarter ended June 30, 2021, and recent business highlights.

• Achilles Therapeutics Enrolls First US Patient in Ongoing Phase I/IIa Study in Advanced Non-small Cell Lung Cancer

  7/1/2021

  Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that the first patient in the United States (US) has been enrolled in the Company’s ongoing Phase I/IIa CHIRON clinical trial.

• Achilles Therapeutics Details Phase I/IIa Clinical Trial Design of CHIRON in Patients with Advanced Non-Small Cell Lung Cancer at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

  6/4/2021

  Achilles Therapeutics plc (NASDAQ: ACHL), today presented a poster at the American Society of Clinical Oncology (ASCO) Annual Meeting 2021, which is being held in a virtual format from June 4-8, 2021.

• Achilles Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Highlights

  5/11/2021

  Reported first clinical data from the CHIRON and THETIS trials and received recommendation from the Independent Data Safety Monitoring Committee to continue trials as planned

• Achilles Therapeutics Receives Horizon 2020 Grant as Part of Neoantigen ConsortiumResearch and Innovation program to develop a tool for the prediction of neoantigen immunogenicity

  5/6/2021

  Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that it is a member of a consortium that has been awarded a grant from Horizon 2020, an EU Research and Innovation program

• Achilles Therapeutics to present at the BofA Securities 2021 Virtual Healthcare Conference

  5/5/2021

  Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that Iraj Ali, Chief Executive Officer, will participate in a fireside chat at the BofA Securities 2021 Virtual Healthcare Conference on Thursday, May 13, 2021, at 9:30 a.m. ET / 2:30 p.m. BST.

• Achilles Therapeutics Appoints Julie O’Neill to Board of Directors and Markwin Velders, Ph.D. joins Scientific Advisory Board

  5/3/2021

  Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announces the appointment of Julie O’Neill as a Non-Executive Director to the Board and Markwin Velders, Ph.D. to its Scientific Advisory Board (SAB)

• Achilles Therapeutics Demonstrates cNeT Product Characterization and Post-Infusion Tracking in a Patient Case Study at the American Association for Cancer Research (AACR) 2021 Annual Meeting

  4/10/2021

  Achilles Therapeutics plc, a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, presented a patient case study from the Company’s ongoing Phase I/IIa THETIS trial in metastatic or recurrent melanoma at the American Association for Cancer Research Annual Meeting 2021.

• 

  Money on the Move: March 31 – April 6

  4/7/2021

  April springs up with showers of cash for these life sciences companies.

• Achilles Therapeutics Announces Closing of $175.5 million Initial Public Offering

  4/6/2021

  Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the closing of its previously announced initial public offering in the United States of 9,750,000 American Depositary Shares (“ADSs”) representing 9,750,000 ordinary shares, at an initial public offering price of $18.00 per ADS

• Achilles Therapeutics Announces Pricing of Initial Public Offering

  3/30/2021

  Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the pricing of its initial public offering in the United States of 9,750,000 American Depositary Shares (“ADSs”)

• Achillion Shareholders Approve Agreement to be Acquired by Alexion

  12/19/2019

  Alexion and Achillion have not yet submitted their filings under the HSR Act, and currently anticipate doing so in January 2020.

• Achilles Therapeutics Appoints Beverley Carr as Chief Business Officer

  10/21/2019

  Achilles Therapeutics, a biopharmaceutical company developing personalised cancer immunotherapies, announces it has appointed Beverley Carr as Chief Business Officer, with effect from 4 November 2019.

• Achilles Therapeutics raises £100 million in oversubscribed Series B financing

  9/3/2019

  Achilles Therapeutics announces it has closed a £100 million Series B financing led by incoming U.S. investor RA Capital Management, corner-stoned by founding investor Syncona and joined by important new investors including Forbion, Invus, Perceptive Advisors and Redmile Group.

• 

  BioSpace Movers and Shakers: Feb. 15

  2/15/2019

  Pharma and biotech companies strengthen their leadership teams with new hires and appointments at Cadent, bluebird, Abeona, Sanofi, and more.

• Achilles Therapeutics receives CTA Approval for Phase I/II Study in Metastatic or Recurrent Melanoma

  2/13/2019

  Achilles Therapeutics (“Achilles”), a biopharmaceutical company developing personalised cancer immunotherapies, today announces the approval by the UK Medicines and Healthcare products Regulatory Agency (MHRA) of its Clinical Trial Application (CTA) to conduct a Phase I/II study using clonal neoantigen targeting T cells (cNeT) in patients with metastatic or recurrent melanoma.

• Achilles Therapeutics appoints Dr Markus Dangl as Chief Scientific Officer

  2/12/2019

  Dr Dangl joins Achilles from Medigene AG where he spent three years as Senior Vice President for Research and Non-clinical Development.

• Achilles Therapeutics receives CTA approval for Phase I/II Study in Non-Small Cell Lung Cancer

  1/21/2019

  Achilles Therapeutics (“Achilles””), a biopharmaceutical company developing personalised cancer immunotherapies, today announces that its Clinical Trial Application (CTA) to conduct a Phase I/II study with its lead product, a tumour-derived T cell therapy targeting clonal neoantigens, in development for the treatment of  advanced Non-Small Cell Lung Cancer (NSCLC), has been approved by the UK regulatory authority, the Medicines and Healthcare products Regulatory Agency (MHRA).